Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Sickle Cell Disease
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Younger than 634 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02675959
- Collaborators
- University of California, Los Angeles
- Medical College of Wisconsin
- Tufts Medical Center
- Baylor College of Medicine
- Johns Hopkins University
- Dana-Farber Cancer Institute
- University of Michigan
- Children's Hospital Los Angeles
- Investigators
- Principal Investigator: Mitchell Cairo, MD New York Medical College
Get Well Soon